January 12, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Pacific Biosciences of California (NASDAQ:PACB) shares over potential securities laws violations by Pacific Biosciences of California and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Pacific Biosciences of California (NASDAQ:PACB) concerning whether a series of statements by Pacific Biosciences of California regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Pacific Biosciences of California reported that its annual Total Revenue rose from $60.59 million in 2014 to $92.78 million in 2015 and that its Net Loss declined from $66.16 million in 2014 to $31.70 million in 2015.

Shares of Pacific Biosciences of California (NASDAQ:PACB) rose to as high as $13.24 per share in late December 2015.

On Decmeber 15, 2016, Pacific Biosciences of California, Inc. (Nasdaq:PACB) announced that F. Hoffman-La Roche Ltd (Roche) has elected to terminate for convenience the development, commercialization and license agreement with Pacific Biosciences for the development and supply of diagnostic products based on the companys Single Molecule, Real-Time (SMRT) technology.

Shares of Pacific Biosciences of California (NASDAQ:PACB) declined to as low as $3.76 per share in late December 2016.

On January 12, 2017, NASDAQ:PACB shares closed at $4.69 per share